Amir Khan
About Me
Dr. Khan has a PhD in cancer antigen discovery for epitope-based vaccine development from Gachon University in South Korea. His first postdoctoral position was at the Immunology Center of Georgia at Augusta, where he studied the autoimmune aspect of cardiovascular disease and was working on the design and development of a tolerogenic vaccine for atherosclerosis. Currently, he is a postdoctoral fellow at Mount Sinai, where he focus on CAR-T cells for cancer treatment, specifically on antigen discovery and uncovering molecular checkpoints to enhance the efficacy of CAR-T cell therapies.
Language
Position
Research Topics
Anti-Tumor Therapy, Cancer, Immunological Tolerance, Immunology, T Cells, Vaccine Development
Multi-Disciplinary Training Areas
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT), Immunology [IMM]
About Me
Dr. Khan has a PhD in cancer antigen discovery for epitope-based vaccine development from Gachon University in South Korea. His first postdoctoral position was at the Immunology Center of Georgia at Augusta, where he studied the autoimmune aspect of cardiovascular disease and was working on the design and development of a tolerogenic vaccine for atherosclerosis. Currently, he is a postdoctoral fellow at Mount Sinai, where he focus on CAR-T cells for cancer treatment, specifically on antigen discovery and uncovering molecular checkpoints to enhance the efficacy of CAR-T cell therapies.
Language
Position
Research Topics
Anti-Tumor Therapy, Cancer, Immunological Tolerance, Immunology, T Cells, Vaccine Development
Multi-Disciplinary Training Areas
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT), Immunology [IMM]
